
Annual report 2024
added 02-21-2026
Sundial Growers Market Cap 2011-2026 | SNDL
As of March 04, 2026 Sundial Growers has a market cap of $ 3.37 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Sundial Growers
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 889 K | 178 M | 103 M | - | - | - | - | - | - | - | - |
All numbers in CAD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 178 M | 889 K | 94 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Drug manufacturers industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Aerie Pharmaceuticals
AERI
|
325 M | - | - | $ 754 M | ||
|
Canopy Growth Corporation
CGC
|
142 M | $ 1.11 | 4.25 % | $ 119 M | ||
|
AcelRx Pharmaceuticals
ACRX
|
22.2 M | - | 7.5 % | $ 6.35 M | ||
|
Catalent
CTLT
|
10.9 B | - | - | $ 11.5 B | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
18 M | - | 0.86 % | $ 117 M | ||
|
DURECT Corporation
DRRX
|
31.8 M | - | - | $ 50.1 M | ||
|
Endo International plc
ENDP
|
68.2 M | - | - | $ 28.9 M | ||
|
Agile Therapeutics
AGRX
|
1.29 M | - | 10.11 % | $ 58.2 M | ||
|
Evoke Pharma
EVOK
|
2.24 M | - | - | $ 36.6 M | ||
|
Alimera Sciences
ALIM
|
101 M | - | - | $ 142 M | ||
|
Evolus
EOLS
|
271 M | $ 5.57 | 34.75 % | $ 359 M | ||
|
Cronos Group
CRON
|
3.63 B | $ 2.65 | 1.92 % | $ 1.38 B | ||
|
Avadel Pharmaceuticals plc
AVDL
|
717 M | - | - | $ 2.06 B | ||
|
Harrow Health
HROW
|
1.93 B | $ 40.0 | 3.61 % | $ 1.47 B | ||
|
Jupiter Wellness
JUPW
|
82.8 M | - | - | $ 33.6 M | ||
|
China Pharma Holdings
CPHI
|
4.54 M | $ 0.59 | 7.93 % | $ 10.3 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
88.6 M | $ 3.8 | -17.03 % | $ 53.4 M | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
966 M | - | -0.1 % | $ 2.03 B | ||
|
HEXO Corp.
HEXO
|
89 M | - | 2.45 % | $ 38.1 M | ||
|
Neoleukin Therapeutics
NLTX
|
1.72 M | - | - | $ 193 M | ||
|
Aurora Cannabis
ACB
|
915 M | $ 3.69 | 5.89 % | $ 86.3 M | ||
|
Athenex
ATNX
|
11.4 M | - | -23.39 % | $ 1.76 M | ||
|
Organogenesis Holdings
ORGO
|
415 M | $ 2.93 | 1.92 % | $ 386 M | ||
|
Emergent BioSolutions
EBS
|
139 M | $ 8.95 | 0.34 % | $ 458 M | ||
|
ProPhase Labs
PRPH
|
131 M | - | - | $ 5.07 M | ||
|
Assertio Holdings
ASRT
|
66.1 M | $ 12.19 | 2.48 % | $ 866 M | ||
|
Radius Health
RDUS
|
378 M | - | - | $ 1.42 B | ||
|
Rockwell Medical
RMTI
|
35.5 M | $ 0.91 | 0.93 % | $ 21.2 M | ||
|
Bausch Health Companies
BHC
|
3.38 B | $ 5.7 | -0.61 % | $ 2.08 B | ||
|
Lannett Company
LCI
|
39.4 M | - | 1.15 % | $ 7.11 M | ||
|
Eagle Pharmaceuticals
EGRX
|
340 M | - | -39.89 % | $ 27.7 M | ||
|
OrganiGram Holdings
OGI
|
382 M | $ 1.42 | 3.28 % | $ 402 M | ||
|
Perrigo Company plc
PRGO
|
1.96 B | $ 11.66 | 2.42 % | $ 1.61 B | ||
|
TherapeuticsMD
TXMD
|
23.9 M | $ 2.25 | 1.35 % | $ 23.5 M | ||
|
Pacira BioSciences
PCRX
|
1.18 B | $ 22.97 | 3.94 % | $ 1.06 B | ||
|
Veru
VERU
|
108 M | $ 2.54 | 0.8 % | $ 343 M | ||
|
PetIQ
PETQ
|
396 M | - | 1.64 % | $ 400 M | ||
|
OptiNose
OPTN
|
192 M | - | - | $ 1.08 B | ||
|
Viatris
VTRS
|
18.4 B | $ 14.88 | -0.1 % | $ 17.9 B | ||
|
PLx Pharma
PLXP
|
118 M | - | -27.8 % | $ 2.56 M | ||
|
Recro Pharma
REPH
|
133 M | - | -4.76 % | $ 65.3 M | ||
|
cbdMD
YCBD
|
1.68 M | $ 0.74 | -4.01 % | $ 3.19 M | ||
|
Relmada Therapeutics
RLMD
|
162 M | $ 4.77 | 2.14 % | $ 144 M | ||
|
SCYNEXIS
SCYX
|
70.3 M | $ 0.76 | 1.21 % | $ 36.4 M | ||
|
Solid Biosciences
SLDB
|
226 M | $ 6.18 | 3.69 % | $ 252 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
3.66 M | $ 2.74 | -0.36 % | $ 3.4 M | ||
|
Tricida
TCDA
|
359 M | - | - | $ 3.25 M | ||
|
Tilray
TLRY
|
1.19 B | $ 7.42 | 0.82 % | $ 4.59 B | ||
|
Zynerba Pharmaceuticals
ZYNE
|
18.8 M | - | - | $ 55.5 M |